You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Treatment of Inflammatory Complications of Respiratory Infection
SBC: Respana Therapeutics, Inc Topic: NIAIDAbstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View
SBC: YAYA SCIENTIFIC LLC Topic: NIBIBPROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
SIRPant Technology for anti-Cancer Immunity
SBC: SIRPANT IMMUNOTHERAPEUTICS INC Topic: 102PROJECT SUMMARY Immune evasion is a hallmark of cancer. Various tumor immunotherapy treatments, such as immune checkpointblockade and cancer vaccination, have been developed to overcome cancer’s ability to avoid immune detectionand destruction; however, the result of these endeavors have not been satisfactory given a number of criticalbarriers. One of these barriers, and a prominent mechanism by ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution
SBC: Trevarx Biomedical, Inc. Topic: 102ABSTRACT: Poly (ADP-ribose) polymerase inhibitors (PARPi’s) have emerged as important therapeutic agents targeting a broadening class of gene mutations approved for treatment of breast, ovarian, prostate, and other cancers. Genomic assays of BRCA-related genes and tumor homologous repair deficiency are used as companion diagnostics for PARPi therapy but have imperfect predictive efficacy for PAR ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Zero Vulnerability Technology: Leveraging Micropatching and Intelligent Software Scrambling for Next Generation Northern Command Application Security
SBC: ARMS CYBER DEFENSE, INC. Topic: AF20CTCSO1Homogeneous software applications employed throughout NORTHCOM and Platform One pose a huge opportunity for adversaries to scale exploits within the defense ecosystem. Unmanned Aerial System (UAS) applications specifically pose a huge attack vector due to
STTR Phase II 2022 Department of DefenseAir Force -
Information Extraction for New Emerging Noisy User-generated Microtext
SBC: INTUIDEX INC Topic: AF19BT006This proposal presents an opportunity to address many challenges of information extraction and related techniques when applied to noisy user-generated microtext in PAI (publicly available information) and military “chat” data, in support of United States Air Force and Air National Guard intelligence analysts leveraging such sources in their missions. Given the breadth of chat data platforms ...
STTR Phase II 2022 Department of DefenseAir Force -
Sense and Avoid Autonomy Capabilities Enabling Orbs
SBC: NEAR EARTH AUTONOMY, INC Topic: AFX20DTCSO1A critical capability needed by unmanned aircraft systems (UAS), both in military and in commercial use, is to sense and avoid other aircraft. Such a capability constitutes a last line of safety when air traffic control is unable to keep aircraft away from each other. This is partly because UAS cannot practically be constrained to assigned corridors but also because these aircraft must fit into cu ...
STTR Phase II 2022 Department of DefenseAir Force -
eQ Propulsor for Drone Applications
SBC: WHISPER AERO INC Topic: AFX20DTCSO1In this Phase II STTR, Whisper Aero is proposing novel ultra-quiet high-performance propulsors that can be applied to Group I, II, and III UAS and consumer drones. In Phase I, Whisper Aero successfully designed, built, and tested an initial design using a comprehensive suite of low-Reynolds number aerodynamic design tools, aero-structural static & modal analyses, rapid manufacturing techniques, a ...
STTR Phase II 2022 Department of DefenseAir Force -
Multidisciplinary Design Framework for Low Noise Propulsors
SBC: WHISPER AERO INC Topic: AFX20DTCSO1In this Phase II STTR, Whisper Aero is proposing an adaptable multidisciplinary design framework for low noise propulsors. It will incorporate the newest industry-standard and open source propulsive design tools across aerodynamics, acoustics, powertrain, and structures disciplines for synthesizing ideal propulsors for Group I, II, and III UAS. In Phase I, Whisper Aero successfully incorporated me ...
STTR Phase II 2022 Department of DefenseAir Force -
A novel PEDF peptide mimetic for diabetic retinopathy
SBC: SKYRAN BIOLOGICS, INC. Topic: NEIAbstract The overall goal of Skyran Biologics is to develop a potent topical therapeutic for diabetic retinopathy (DR), a leading cause of vision loss globally. Our research team identified Pigment Epithelium-Derived Factor (PEDF) and showed it is expressed in the eye and provides significant protection to the injured retina. Since its discovery, we identified a 44-mer N-terminus bioactive region ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health